Penglase Ross, Girgis Laila, Englert Helen, Brennan Xavier, Jabbour Andrew, Kotlyar Eugene, Ma David, Moore John
Department of Rheumatology, St. Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
University of New South Wales, Sydney, NSW, Australia.
J Scleroderma Relat Disord. 2023 Jun;8(2):87-100. doi: 10.1177/23971983221145639. Epub 2023 Feb 7.
Autologous haematopoietic stem cell transplantation is now well-established as an effective treatment for severe systemic sclerosis with clear demonstration of favourable end-organ and survival outcomes. Treatment-related cardiotoxicity remains the predominant safety concern and contraindicates autologous haematopoietic stem cell transplantation in patients with severe cardiopulmonary disease. In this review, we describe the cardiovascular outcomes of autologous haematopoietic stem cell transplantation recipients, discuss the potential mechanisms of cardiotoxicity and propose future mitigating strategies.
自体造血干细胞移植现已成为治疗重度系统性硬化症的有效方法，有力证明了其对终末器官和生存结局的良好影响。与治疗相关的心脏毒性仍是主要的安全问题，也是重度心肺疾病患者进行自体造血干细胞移植的禁忌证。在本综述中，我们描述了自体造血干细胞移植受者的心血管结局，讨论了心脏毒性的潜在机制，并提出了未来的缓解策略。
